PharmaJet, the maker of innovative, needle-free injection technology, announced that the National Institutes of Health will use the PharmaJet Stratis® needle-free device in a DNA vaccine clinical trial for the Zika virus.
DNA vaccines are the way of the future. Unlike traditional vaccines, like for flu or measles, that contain whole viruses, DNA vaccines contain just a tiny piece of a virus’s genetic code, making them safe and easy to work with. For these vaccines to work however, it is not enough to just get into the bloodstream like a traditional injection, the DNA vaccine must get directly into the cells. For that purpose, a new delivery method was needed.
“The PharmaJet needle-free device is ideal to deliver DNA vaccines and we are collaborating with several partners in this development effort. The device uses a narrow stream of fluid that goes through the skin, directly into the cells, without a needle, in about 1/10 th of a second. It offers a safe, fast and easy-to-use method to deliver the vaccine,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery
